CGEM News
Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?
The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 129.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?
The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 129.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases
Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor...
Business Wire
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with epidermal growth factor...
Business Wire
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer
Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been selected for presentation in the Presidential Symposium 2 at the International Association for the Study of Lung Cancer's...
Business Wire
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the...
Business Wire
Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell Technology Inc (NASDAQ: MRVL) surged in pre-market trading after securing a spot in the S&P 500...
Benzinga
Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks
Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks $NTHI, $ORKA, $ABVX, $CGEM, $SYRE, $APGE
24-7 Market News
The Biology Came First.
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at...
Business Wire
Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock
Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 8,000 shares of the business's stock in a transaction that occurred on Tuesday, May 5th. The shares were...
MarketBeat